Bildkälla: Stockfoto

Pila Pharma: Initial results from the 13-week safety study - Redeye

Redeye feels encouraged that the preclinical preparations of XEN-DIA keep progressing according to plan. We leave a short comment.

Redeye feels encouraged that the preclinical preparations of XEN-DIA keep progressing according to plan. We leave a short comment.
Börsvärldens nyhetsbrev
ANNONSER